Clinical trials: NSCLC Stage II
ALK-positive Non-small Cell Lung Cancer
Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma
The purpose of this study is to see if Ceritinib can target ALK in non-small cell lung cancer and slow down cancer growth and prevent it from spreading.
- Trial name
- NCT02513667
- Testing
- Ceritinib, Stereotactic ablative body radiation
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Texas Southwestern Medical Center
Lung Cancer
Pharmacogenomic & Phase II Study of Gemcitabine and Pemetrexed in Non-Small-Cell Lung Cancer.
This study will evaluate the efficacy and safety of chemotherapy given prior to having lung cancer surgically removed. Patients with resectable non-small cell lung cancer will receive gemcitabine and pemetrexed together for 4…
- Trial name
- NCT00226577
- Testing
- Gemcitabine, Pemetrexed, Surgery
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Non-Small Cell Lung Cancer
Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)
This study will treat patients with advanced NSCLC with EGFR or HER2 mutation who have progressed following prior therapy. This is the first time this drug is tested in patients, and so it will help to understand what type of…
- Trial name
- NCT03974022
- Testing
- Sunvozertinib
- Where
- 124 sites in United States, Argentina and 11 more
- Volunteers
- 315 people
- Sponsor
- Dizal Pharmaceuticals
Carcinoma, Non-Small-Cell Lung
A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)
This is a multi-center, open-label, Phase II study of intravenous (IV) SHR-1210 at 200mg, q2w in combination with Apatinib at two dose levels in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).
- Trial name
- NCT03083041
- Testing
- SHR-1210, Apatinib
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Carcinoma, Non-Small-Cell Lung
Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer
The purpose of this study is to determine whether treatment with carboplatin and gemcitabine combined with bevacizumab every two weeks will provide increased survival.
- Trial name
- NCT00400803
- Testing
- Gemcitabine, Carboplatin, Bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
This randomized phase II trial studies how well erlotinib hydrochloride or crizotinib with chemoradiation therapy works in treating patients with stage III non-small cell lung cancer.
- Conditions
- Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7
- Trial name
- NCT01822496
- Testing
- Radiation Therapy, Carboplatin, Cisplatin
- Where
- 174 sites in United States
- Volunteers
- 59 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer, Non-Small Cell
An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer
This is a phase II, open-label, multicenter, randomized study to evaluate the efficacy and safety of GSK1120212 compared with docetaxel in the second line setting for subjects with locally advanced or metastatic (Stage IV)…
- Trial name
- NCT01362296
- Testing
- GSK1120212, docetaxel
- Where
- 60 sites in United States, France and 6 more
- Volunteers
- 134 people
- Sponsor
- GlaxoSmithKline
Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer
This research study examines the use of Abraxane (paclitaxel albumin-stabilized nanoparticle formulation) in patients with lung cancer. Abraxane is a chemotherapy approved to treat patients with breast cancer.
- Trial name
- NCT01620190
- Testing
- Laboratory Biomarker Analysis, Paclitaxel Albumin-Stabilized Nanoparticle Formulation
- Where
- 12 sites in United States
- Volunteers
- 26 people
- Sponsor
- University of Washington
Non Small Cell Lung Cancer
Trial of Poor Performance Status Patients (ToPPS)
The purpose of this trial is to evaluate three treatment regimens in patients with stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) with a performance status of 2 and who were not previously treated.
- Trial name
- ToPPS (NCT00892710)
- Testing
- Pemetrexed, Bevacizumab, Carboplatin
- Where
- 27 sites in United States
- Volunteers
- 172 people
- Sponsor
- SCRI Development Innovations, LLC
Metastatic Non Small Cell Lung Cancer
Switch Maintenance Pembrolizumab in Patients With NSCLC After First Line Platinum Doublet Chemotherapy
Single arm one stage Phase II study: post 4-6 cycles platinum doublet chemotherapy for patients with metastatic Non Small Cell Lung Cancer (NSCLC) offering Pembrolizumab as maintenance therapy to non-progressors with primary…
- Trial name
- SWIPE (NCT02705820)
- Testing
- Pembrolizumab
- Where
- Cyprus
- Volunteers
- 48 people
- Sponsor
- Bank of Cyprus Oncology Centre
Lung Diseases, Carcinoma, Non-Small-Cell Lung
Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)
Open-label, non-randomized, phase II multi-centre controlled clinical trial. 51 non-resectable stage IIIA-IIIB non-small cell lung cancer patients will be enrolled in this trial to evaluate the efficacy of the treatment…
- Conditions
- Lung Diseases, Carcinoma, Non-Small-Cell Lung, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
- Trial name
- APOLO (NCT04776447)
- Testing
- Carboplatin, Placlitaxel, Atezolizumab
- Where
- 22 sites in Spain
- Volunteers
- 38 people
- Sponsor
- Fundación GECP
Non Small Cell Lung Cancer (NSCLC)
Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)
This study compared two doses of pembrolizumab (MK-3475) versus docetaxel in participants with non-small cell lung cancer (NSCLC) who had experienced disease progression after platinum-containing systemic therapy.
- Trial name
- NCT01905657
- Testing
- Pembrolizumab, Docetaxel
- Volunteers
- 1,034 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Small-Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4
A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer
The optimal prioritization of second-line chemotherapy and immune therapy based on demographic or biomarker data is an area of ongoing investigation.
- Conditions
- Non-Small-Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4, Nonsmall Cell Lung Cancer, Non Small Cell Lung Cancer Recurrent
- Trial name
- NCT02967133
- Testing
- Nivolumab, nab-paclitaxel
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- Alliance Foundation Trials, LLC.
Advanced Cancer, Advanced Solid Tumor
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
This study is an open-label, multi-arm, parallel cohort, dose validation and expansion design. The study is modular in design, allowing evaluation of the safety, efficacy and pharmacokinetics (PK) of NUC-3373 in combination with…
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Neoplasm Malignant, Metastatic Cancer
- Trial name
- NCT05714553
- Testing
- Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab
- Where
- 4 sites in United Kingdom
- Volunteers
- 19 people
- Sponsor
- NuCana plc
Adenocarcinoma of the Lung, Large Cell Lung Cancer
S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib
This randomized phase II trial studies how well pemetrexed disodium with or without crizotinib works in treating patients with stage IV non-small cell lung cancer that has progressed after crizotinib.
- Conditions
- Adenocarcinoma of the Lung, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT02134912
- Testing
- crizotinib, pemetrexed disodium, laboratory biomarker analysis
- Where
- 167 sites in United States
- Volunteers
- 1 people
- Sponsor
- SWOG Cancer Research Network
Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
This randomized phase II/III trial studies how well giving maintenance chemotherapy with or without local consolidation therapy works in treating patients with stage IV non-small cell lung cancer.
- Trial name
- NCT03137771
- Testing
- 3-Dimensional Conformal Radiation Therapy (3D-CRT), Docetaxel, Gemcitabine
- Where
- 301 sites in United States, Canada and 2 more
- Volunteers
- 218 people
- Sponsor
- NRG Oncology
Non-Small Cell Lung Cancer (NSCLC)
Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation
The purpose of the study was to learn whether the study treatment (capmatinib), which already shows efficacy and safety in non-Chinese patients, could help Chinese patients with controlling their lung cancer in a safe way.
- Trial name
- GeoMETry-C (NCT04677595)
- Testing
- Capmatinib
- Where
- 17 sites in China
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Lung Cancer
Iressa Re-Challenge in Advanced NSCLC EGFR M+ Patients Who Responded to Gefitinib USed as 1st Line or Previous Treatment
the primary objective is to characterise the impact of gefitinib on the Response Evaluation Criteria in Solid Tumours (RECIST) based assessments; objective response rate (ORR ; confirmed complete response(CR) or partial response…
- Trial name
- ICARUS (NCT01530334)
- Testing
- Gefitinib 250mg
- Where
- 24 sites in Italy
- Volunteers
- 61 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Cancer
Zactima in Non Small Cell Lung Cancer (NSCLC) ELderly Patients In Combination With or Versus Gemcitabine
The primary objective of this study is to demonstrate an improvement in Progression-Free Survival (PFS) for the combination of vandetanib plus gemcitabine compared with gemcitabine plus placebo in chemonaïve (not including an…
- Trial name
- ZELIG (NCT00753714)
- Testing
- ZD6474, Vandetanib, Gemcitabine
- Where
- 15 sites in Italy
- Volunteers
- 124 people
- Sponsor
- Genzyme, a Sanofi Company
Non-small Cell Lung Cancer
Trial Comparing Cetuximab With Pemetrexed/Cetuximab Therapy for Non-Small Cell Lung Cancer
The purpose of the study is to determine in patients with Non Small Cell Lung Cancer refractory to previous chemotherapy whether concomitant treatment with cetuximab and pemetrexed improves progression-free survival compared with…
- Trial name
- NCT00203931
- Testing
- Cetuximab, Pemetrexed
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- University of Chicago